The 4,500 sq ft facility, named Ancoris, will support clinical and commercial manufacturing of Krystal’s lead product candidate, KB103, for the treatment of DEB
Entera will use its proprietary drug delivery platform to develop oral formulations for one preclinical large molecule program that Amgen has selected.